Cytokinetics, Inc. (CYTK)
65.60
-0.02
(-0.03%)
USD |
NASDAQ |
Oct 02, 16:00
65.59
-0.01
(-0.02%)
After-Hours: 20:00
Cytokinetics EPS Diluted (Quarterly) : -1.505 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.505 |
| March 31, 2026 | -1.671 |
| December 31, 2025 | -1.495 |
| September 30, 2025 | -2.552 |
| June 30, 2025 | -1.125 |
| March 31, 2025 | -1.362 |
| December 31, 2024 | -1.271 |
| September 30, 2024 | -1.364 |
| June 30, 2024 | -1.312 |
| March 31, 2024 | -1.331 |
| December 31, 2023 | -1.382 |
| September 30, 2023 | -1.347 |
| June 30, 2023 | -1.343 |
| March 31, 2023 | -1.380 |
| December 31, 2022 | -1.451 |
| September 30, 2022 | -1.518 |
| June 30, 2022 | -0.2312 |
| March 31, 2022 | -1.052 |
| December 31, 2021 | -0.3636 |
| September 30, 2021 | -0.9472 |
| June 30, 2021 | -0.8578 |
| March 31, 2021 | -0.6616 |
| December 31, 2020 | -0.6202 |
| September 30, 2020 | -0.0465 |
| June 30, 2020 | -0.6842 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.6648 |
| December 31, 2019 | -0.5182 |
| September 30, 2019 | -0.5043 |
| June 30, 2019 | -0.557 |
| March 31, 2019 | -0.5357 |
| December 31, 2018 | -0.484 |
| September 30, 2018 | -0.403 |
| June 30, 2018 | -0.51 |
| March 31, 2018 | -0.5601 |
| December 31, 2017 | -0.75 |
| September 30, 2017 | -0.60 |
| June 30, 2017 | -0.60 |
| March 31, 2017 | -0.62 |
| December 31, 2016 | 0.16 |
| September 30, 2016 | 0.77 |
| June 30, 2016 | -0.29 |
| March 31, 2016 | -0.31 |
| December 31, 2015 | -0.24 |
| September 30, 2015 | -0.23 |
| June 30, 2015 | -0.27 |
| March 31, 2015 | -0.23 |
| December 31, 2014 | 0.23 |
| September 30, 2014 | -0.16 |
| June 30, 2014 | -0.23 |
| March 31, 2014 | -0.27 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Bristol Myers Squibb Co. | 1.620 |
| Ionis Pharmaceuticals, Inc. | -0.6931 |
| Vertex Pharmaceuticals, Inc. | 4.310 |
| Krystal Biotech, Inc. | 1.786 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -198.76M |
| Revenue (Quarterly) | 28.62M |
| Total Expenses (Quarterly) | 227.39M |
| Enterprise Value | 9.205B |
| Gross Profit Margin (Quarterly) | 67.78% |
| Profit Margin (Quarterly) | -694.4% |
| Earnings Yield | -11.01% |
| Normalized Earnings Yield | -10.05 |